Skip to content
Peptide Atlas
All peptides

Epithalon

Tier 3 · Reported use
Also known as Epitalon · Epithalone · AEDG

The strongest evidence present is Tier 1 human observational data (e.g.,1 on 6-sulfatoxymelatonin excretion and circadian gene normalization; Russian mortality cohorts; epithalamin geroprotector trials). However, these human data are limited to small, often decades-old observational cohorts with variable blinding, largely from a single Russian group (Khavinson/St. Petersburg Institute of Bioregulation and Gerontology), with no human RCTs or hard-endpoint trials. The bulk of substantive mechanistic evidence (telomerase/telomere, lifespan, tumor, oocyte, gene expression) is in vitro and animal, and roughly half the ~110 articles are in Russian.

Half-life
~0.5 h
Routes
Subcutaneous injection · Intramuscular injection · Intranasal (parent pineal preparation)
Goals
longevity · cognitive · immune support
Cost / mg
Not recorded

How it works

Epithalon is a small synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a natural extract from the pineal gland. Researchers report that it can switch on telomerase — the enzyme that maintains the protective caps (telomeres) on chromosomes — by increasing production of the hTERT component, and that in lab-grown human cells this lengthened telomeres and let cells divide past their usual limit. It is also studied as a regulator of the body clock, appearing to help restore normal nighttime melatonin production and circadian rhythms, and it acts as an antioxidant. At a deeper level it is proposed to enter the cell nucleus and interact directly with DNA and histone proteins to influence which genes are turned on or off.

Overview

Overview

Epithalon (also spelled Epitalon or Epithalone, and known as AEDG) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine). It has a molecular weight of approximately 390.35 g/mol, the molecular formula C14H22N4O9, and CAS number 307297-39-8.

The peptide was synthesized based on the amino acid composition of epithalamin, a crude polypeptide fraction extracted from bovine pineal glands, and is considered the active tetrapeptide isolate from that extract. It was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with development beginning in the 1980s. The AEDG sequence was reportedly first detected as a natural component of the pineal gland in 2017, and some sources describe it as a naturally occurring peptide. It has been studied for roughly 25-30+ years using in vitro, in vivo, and in silico methods, generating around 110 published articles on epithalamin and epithalon (at least half of which are in Russian).

Reported Mechanisms and Findings

Telomerase and telomeres

A 2003 paper by Khavinson and colleagues (PMID 12937682) reported that epithalon induced telomerase activity (hTERT expression), restored enzymatic telomerase activity, and elongated telomeres in cultured human somatic cells, including telomerase-negative fetal fibroblasts. Treated fibroblasts reportedly proliferated to passage 44, exceeding the Hayflick limit (~passage 34) seen in controls. Reported figures include a 2.4x increase in telomerase activation and a +33% increase in telomere length. These findings were reportedly replicated in vitro in 2025 (Siddiqui/Al-Dulaimi et al., PMID 40908429), which described dose-dependent telomere extension in normal cells via hTERT/telomerase upregulation; in telomerase-positive cancer lines the effect reportedly proceeded mainly via the Alternative Lengthening of Telomeres (ALT) pathway.

Epigenetic and transcriptional regulation

Short peptides such as AEDG are proposed to penetrate cell and nuclear membranes and interact directly with DNA and histones. In silico work reports preferential binding to linker histones H1.3 and H1.6 and interaction with specific promoter DNA sequences. In human gingival mesenchymal stem cells, AEDG increased neurogenic differentiation markers (Nestin, GAP43, βTubulin III, Doublecortin) 1.6-1.8x, and in cultured cells it decreased the senescence markers p16 and p21 by 1.56-2.44x.

Neuroendocrine / circadian and antioxidant effects

Epithalon is reported to influence melatonin synthesis and restore circadian rhythms. In old rhesus monkeys it caused a threefold increase in nocturnal melatonin peaks and restored circadian melatonin and cortisol rhythms. In a Tier-1 human observational study it increased urinary 6-sulfatoxymelatonin excretion 1.7x and normalized circadian gene expression (Clock, Csnk1e, Cry2) in leukocytes. It is described as a potent antioxidant, comparable to melatonin and roughly 1000-fold more potent than epithalamin, and in aging oocyte cultures it reduced ROS, increased mitochondrial membrane potential and mtDNA copy number, and reduced apoptosis.

Animal longevity and anti-tumor data

Epithalon/epithalamin reportedly increased lifespan in flies, mice, and rats (roughly 10-30% in rodents; +12.3% mean lifespan in CBA mice; 1.8x lower spontaneous tumor incidence in SHR mice). In transgenic HER-2/neu breast cancer mice, dosing (1 mg SC 5x/week) prolonged average and maximum lifespan, increased tumor-free animals 3.7-fold, and reduced lung metastases, probably via suppression of HER-2/neu expression.

Evidence Context and Caveats

The strongest human evidence consists of small observational cohorts, several from Russian clinical groups, reporting restored melatonin rhythms, improved sleep, immune-cell changes, retinal-function improvements, and (in cohorts followed 6-8 years, often combined with thymalin) reduced mortality — findings that have not been independently confirmed. There are no human RCTs or hard-endpoint trials demonstrating that epithalon extends human lifespan. Much of the underlying literature is old, in Russian, and preclinical. Most human and telomerase research originates from a single research group, and Western replication of the telomerase effect at the same magnitude, and of the epigenetic binding data, is limited. Several specific claims (anti-tumor effects in breast/colorectal cancer, gonadotropin effects, orthopaedic-recovery use, diabetic-retinopathy application, histone binding energies, cardiac gene-expression data) rest on single sources.

Regulatory Status

Epithalon is not approved for any indication in the US, has undergone no FDA or EMA regulatory review, was designated FDA Category 2 (October 2023), and is banned from compounding. It is a research compound only.

What the research shows

161 findings extracted from the 20 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 5 human study findings, 25 animal findings, 8 in vitro findings, 3 expert opinion findings and 2 theoretical findings.

  • human studyAEDG peptide increases 6-sulfatoxymelatonin (6-SOMT) excretion in the urine of middle-aged people1

  • human studyEpithalamin demonstrates geroprotector activity in humans in clinical trials12

  • human studyEpitalon improves the visual functions in patients with pigmental retinal degeneration12

  • human studyNo human studies regarding effects on cognition or neuroprotection; however, some clinical evidence suggests it may decrease human mortality15

  • human studySeveral Russian clinical trials suggest epithalamin may decrease mortality in older adults with cardiovascular disease, but these results have not been independently confirmed15

  • animalEpitalon exerts geroprotective and neuroendocrine effects4

  • animalAEDG peptide increases longevity in animals8

  • animalAEDG peptide decreases experimental cancerogenesis8

Show 35 more findings

  • animalEpithalon causes a threefold increase in nocturnal melatonin peaks in old rhesus monkeys10

  • animalEpithalon prolonged the average lifetime of transgenic FVB/N mice carrying HER-2/neu breast cancer gene by 13.5%11

  • animalEpithalon prolonged the maximum lifetime of transgenic FVB/N mice by 13.9%11

  • animalEpithalon prolonged the average lifetime of animals without neoplasms by 34.2%11

  • animalEpithalon decelerated the development of age-related disturbances in reproductive activity11

  • animalEpithalon suppressed the formation of neoplasms11

  • animalEpithalon decreased the incidence of lung metastases by 1.6 times11

  • animalEpithalon decreased the incidence of multiple tumors by 2 times11

  • animalEpithalon 3.7-fold increased the number of mice without breast tumors11

  • animalEpithalon decreased the number of animals with 6 or more breast tumors by 3 times11

  • animalEpithalon prolonged the lifetime of mice with breast tumors by 1.4 times11

  • animalEpithalamin increases melatonin production by the pineal gland of rats12

  • animalEpithalamin improves immunological parameters in rats and mice12

  • animalEpithalamin produces anticarcinogenic effects in different experimental models12

  • animalEpithalamin restores the reproductive function in old rats12

  • animalEpithalamin increases the lifespan in rats, mice, and fruit flies12

  • animalEpitalon reproduces the effects of Epithalamin including geroprotector activity12

  • animalEpitalon increases the lifespan of mice and fruit flies12

  • animalEpitalon restores the circadian rhythms of melatonin and cortisol production in old rhesus monkeys12

  • animalEpitalon prolongs the functional integrity of the eye retina in Campbell rats with hereditary Retinitis Pigmentosa12

  • animalBoth epithalamin and epithalon may increase lifespan in flies, mice and rats15

  • animalAnimal studies show meaningful lifespan extension in mice, rats, and Drosophila16

  • in vitroIn normal cells, epitalon demonstrated dose-dependent telomere length extension through hTERT and telomerase upregulation5

  • in vitroEpitalon restored impaired wound healing in HG-injured ARPE-19 cells6

  • in vitroEpitalon treatment significantly decreased frequency of spindle defects during aging at 12h and 24h of culture7

  • in vitroEpitalon treatment significantly decreased abnormal distribution of cortical granules during aging at 12h and 24h of culture7

  • in vitroEpitalon decreased apoptosis of oocytes by 24h of aging7

  • in vitroAEDG peptide decreased p16 and p21 mRNA expression by 1.56-2.44 times in comparison with the control group9

  • in vitroKED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group9

  • in vitroEpithalon reactivates telomerase (hTERT) in senescent human fetal fibroblasts and extends replicative lifespan past the Hayflick limit16

  • expert opinionThe telomerase data is primarily from one research group over four decades16

  • expert opinionThere is no human trial showing Epithalon extends human life16

  • expert opinionPreclinical studies on therapeutic peptides including epithalon are promising, but there is a current lack of clinical trials18

  • theoreticalNon-approved peptides showed promising preclinical findings2

  • theoreticalEpitalon has been extensively studied using in vitro, in vivo, and in silico methods over the last 25 years3

How it works

Based on 4 human study findings, 28 animal findings, 28 in vitro findings, 4 expert opinion findings and 19 theoretical findings.

  • human studyAEDG peptide normalized circadian Clock and Csnk1e genes hyper expression in leukocytes in middle-aged people with reduced melatonin-producing epiphysis function1

  • human studyAEDG peptide increases Cry2 gene hypo expression in peripheral blood lymphocytes in people with reduced melatonin-producing epiphysis function1

  • human studyAEDG peptide restores epiphysis melatonin-producing function by regulation of human circadian genes expression1

  • human studyEpithalamin stimulates melatonin production in elderly adults with pineal gland dysfunction and in old rats15

  • animalEpitalon has antioxidant effects3

  • animalEpitalon has neuroprotective effects3

  • animalEpitalon has antimutagenic effects3

  • animalEpitalon exerts direct influence on melatonin synthesis3

Show 75 more findings

  • animalEpitalon modulates the mitogenic activity of murine thymocytes3

  • animalEpitalon enhances the activity of AChE (acetylcholinesterase)3

  • animalEpitalon enhances the activity of BuChE (butyrylcholinesterase)3

  • animalEpitalon enhances the activity of telomerase3

  • animalEpitalon demonstrates antioxidant, neuro-protective, and antimutagenic effects4

  • animalEpitalon exerts a direct influence on melatonin synthesis4

  • animalEpitalon alters the mRNA levels of interleukin-24

  • animalEpitalon modulates the mitogenic activity of murine thymocytes4

  • animalEpitalon enhances the activity of various enzymes, including AChE, BuChE, and telomerase4

  • animalAEDG peptide (Ala-Glu-Asp-Gly, Epitalon) regulates the function of the pineal gland, the retina, and the brain8

  • animalThe geroprotective effect of AEDG and KED peptide was shown early in animal and cells models9

  • animalEpithalon possesses geroprotective activity11

  • animalEpithalon inhibits breast carcinogenesis in transgenic mice, probably related to suppression of HER-2/neu expression11

  • animalEpithalamin stimulates antioxidant defenses12

  • animalShort peptide preparations produce changes in gene expression12

  • animalEpithalon modulated expression of 98 clones out of 15,247 clones from a cDNA library in the heart of mice13

  • animalEpithalon alone or in combination with Vilon activated expression of 194 clones (maximally by 6.61 times)13

  • animalEpithalon alone or in combination with Vilon inhibited expression of 48 clones (maximally by 2.71 times)13

  • animalEpithalon has specific effects on gene expression in mouse heart13

  • animalPreclinical studies suggest epithalamin may have anti-oxidant activity in the brain and increase melatonin levels15

  • animalEpithalon failed to stimulate melatonin production in rats but was reported to increase melatonin levels in older primates15

  • animalLower levels of DNA damage were observed in senescence-accelerated mice (SAMP-1) treated with epithalon, an effect not observed with melatonin treatment15

  • animalEpithalon may cross the blood-brain barrier, where it may stimulate cortical neurons and increase levels of phosphor-CREB, a DNA-binding protein important in learning and memory15

  • animalBoth epithalamin and epithalon show antioxidant activity and may improve organismal antioxidant defense systems in flies and rats15

  • in vitroEpithalon peptide induces telomerase activity in human somatic cells2

  • in vitroEpithalon peptide induces telomere elongation in human somatic cells2

  • in vitroEpitalon is a tetrapeptide with amino acid composition Ala-Glu-Asp-Gly (AEDG)3

  • in vitroEpitalon was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract3

  • in vitroEpitalon alters the mRNA levels of interleukin-23

  • in vitroEpitalon is known for its anti-aging effects on mammalian cells5

  • in vitroAnti-aging effects occur through the induction of telomerase enzyme activity5

  • in vitroInduction of telomerase leads to extension of telomere length5

  • in vitroIn cancer cells, significant telomere length extension occurred through ALT (Alternative Lengthening of Telomeres) activation5

  • in vitroOnly a minor increase in ALT activity was observed in normal cells5

  • in vitroAEDG (Ala-Glu-Asp-Gly, Epitalon) is a synthetic tetrapeptide6

  • in vitroShort peptides have antioxidant, antimicrobial, and anti-inflammatory effects6

  • in vitroHigh glucose (HG) exposure delayed wound healing in ARPE-19 cells6

  • in vitroHigh glucose exposure increased intracellular levels of reactive oxygen species (ROS)6

  • in vitroHigh glucose exposure decreased antioxidant gene expression6

  • in vitroHigh glucose induced epithelial-mesenchymal transition (EMT)6

  • in vitroHigh glucose upregulated fibrosis-related genes6

  • in vitroHG-induced EMT contributes to subretinal fibrosis in diabetic retinopathy6

  • in vitroEpitalon inhibited hyperglycemia-induced EMT and fibrosis6

  • in vitro0.1mM Epitalon reduced intracellular reactive oxygen species in oocyte culture7

  • in vitroEpitalon increased mitochondrial membrane potential in aging oocytes7

  • in vitroEpitalon increased DNA copy number of mitochondria in aging oocytes7

  • in vitroAEDG peptide induces neuronal cell differentiation in retinal and human periodontal ligament stem cells8

  • in vitroAEDG peptide increased the synthesis of neurogenic differentiation markers: Nestin, GAP43, β Tubulin III, Doublecortin in hGMSCs8

  • in vitroAEDG peptide increased Nestin, GAP43, β Tubulin III and Doublecortin mRNA expression by 1.6-1.8 times in hGMSCs8

  • in vitroAEDG peptide preferably binds with H1/6 and H1/3 histones at His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites which interact with DNA8

  • in vitroAEDG peptide can epigenetically regulate neuronal differentiation gene expression and protein synthesis in human stem cells8

  • in vitroEpithalamin augments the in vitro outgrowth of explants from the pineal gland but not from other tissues12

  • expert opinionEpithalon is a synthetic four-amino-acid peptide — Ala-Glu-Asp-Gly16

  • expert opinionEpithalon identified by Vladimir Khavinson's group as the active component of Epithalamin, a bovine pineal gland extract16

  • expert opinionPeptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.17

  • expert opinionEpithalon is a recovery-enhancing agent that targets circadian and mitochondrial regulators18

  • theoreticalEpitalon is a tetrapeptide with amino acid sequence Ala-Glu-Asp-Gly (AEDG)4

  • theoreticalEpitalon was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract4

  • theoreticalEpitalon is a synthetic short peptide made of four amino acids (alanine, glutamic acid, aspartic acid, and glycine)7

  • theoreticalEpitalon is based on a natural peptide called epithalamion extracted from the pineal gland7

  • theoreticalEpitalon is a potent antioxidant, comparable to melatonin7

  • theoreticalAEDG peptide and histones H1/3, H1/6 binding may provide an increase of neuronal differentiation gene transcription8

  • theoreticalShort peptides had geroprotective properties and stimulated stem cell differentiation9

  • theoreticalAge-related changes in the pineal gland are functional rather than organic10

  • theoreticalDietary restriction ameliorates or inhibits some age-related impairments of the pineal gland10

  • theoreticalS-adenosylmethionine ameliorates or inhibits some age-related impairments of the pineal gland10

  • theoreticalMAO-A inhibitors ameliorate or inhibit some age-related impairments of the pineal gland10

  • theoreticalEpithalon effects markedly overlap with melatonin effects10

  • theoreticalEpithalon targets may include transcription factors specific for pineal gland and retina that exhibit impaired functions in aged pineal gland10

  • theoreticalEpitalon (Ala-Glu-Asp-Gly) is a tetrapeptide specific for pineal gland and eye retina12

  • theoreticalShort peptides binding specific DNA sequences to regulate gene expression16

  • theoreticalShort peptides are molecules with small molecular weight, capable of penetrating the cell membrane and nuclear membrane for epigenetic regulation of gene expression19

  • theoreticalShort peptides can take part in activation of the signaling pathways regulating expression of differentiation genes19

  • theoreticalShort peptides can interact with histones changing the availability of genes for transcription, regulate gene methylation and activate or inhibit their expression19

  • theoreticalShort peptides can directly interact with the DNA19

Dosing

Based on 1 expert opinion finding and 5 anecdotal findings.

  • expert opinionSignificant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy for peptide therapeutics including epitalon.17

  • anecdotalThe most common protocol is 0.5–1.0 mg daily via subcutaneous injection for 10–20 days, repeated twice per year with a minimum 4-month pause14

  • anecdotalStandard cycle: 5 mg (5,000 mcg) sub-Q daily for 20 consecutive days16

  • anecdotalAlternate dosing: 10 mg daily for 10 days16

  • anecdotalOff period: 4–6 months between cycles16

  • anecdotalAnnual frequency: 1–2 cycles per year16

How the body handles it

Based on 1 expert opinion finding, 1 anecdotal finding and 1 theoretical finding.

  • expert opinionHalf-life is tiny. Epithalon is chewed up by aminopeptidases in minutes16

  • anecdotalReconstitute a 10 mg vial with 2 mL BAC → 5 mg/mL16

  • theoreticalEpithalon is a synthetic peptide Ala-Glu-Asp-Gly designed based on amino acid content of pineal peptide extract Epithalamin10

Safety and side effects

Based on 2 human study findings, 1 animal finding, 1 expert opinion finding and 3 anecdotal findings.

  • human studyLimited evidence suggests epithalamin is likely safe for long term use15

  • human studyTwo 3-year epithalamin treatment trials (one with a 12-year follow-up) reported no severe adverse events in older adults and preclinical studies support a favorable safety profile15

  • animalKhavinson's tumor data shows lower spontaneous tumor incidence in his mouse cohorts16

  • expert opinionNon-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.17

  • anecdotalVivid dreams — very common, almost universal16

  • anecdotalMild drowsiness the next day at higher doses16

  • anecdotalInjection site tenderness — minor, brief16

What people use it for

Based on 4 animal findings, 2 in vitro findings, 5 expert opinion findings, 1 anecdotal finding and 3 theoretical findings.

  • animalEpitalon exerts geroprotective and neuroendocrine effects3

  • animalEpithalon produces life extension in mice10

  • animalEpithalon produces life extension in fruit flies10

  • animalEpithalon postpones vision loss in Campbell rats with hereditary pigmental dystrophy10

  • in vitroEpitalon can delay the aging process of oocytes via modulating mitochondrial activity and ROS levels7

  • in vitroAEDG and KED peptides could be used as supplementary substances in a culture medium to delay the expression of senescence markers in long term stem cell cultivation9

  • expert opinionAEDG peptide is a geroprotector1

  • expert opinionA strong link exists between telomere length and aging-related diseases5

Show 7 more findings

  • expert opinionTelomeres are considered to be one of the biomarkers of aging5

  • expert opinionEpitalon is identified as a peptide with applications in telomere biology17

  • expert opinionEpithalon is used in the management of orthopaedic injuries18

  • anecdotalDeep sleep the first few nights — the signature effect16

  • theoreticalIncreasing or maintaining telomere length may contribute to healthy aging and longevity5

  • theoreticalEpitalon could be used as a therapeutic strategy for diabetic retinopathy6

  • theoreticalEpitalon may confer longevity benefits7

Other findings

Based on 3 expert opinion findings and 1 theoretical finding.

  • expert opinionEpitalon has been extensively studied using in vitro, in vivo, and in silico methods over the last 25 years4

  • expert opinionEpithalamin is a crude polypeptide extract of bovine pineal glands while epithalon is a tetrapeptide isolate (Ala-Glu-Asp-Gly) from epithalamin that can also be made synthetically15

  • expert opinionThere is no evidence to suggest that either epithalamin or epithalon affects APOE4 carriers differently than non-carriers15

  • theoreticalEpitalon is a naturally occurring tetrapeptide5

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

There are no human RCTs or hard-endpoint trials showing epithalon extends human lifespan.

Multiple sources state no large-scale randomized controlled trials exist in humans, no Phase 2/3 hard-endpoint trials have been published, and there is no human trial showing epithalon extends human life. Human data is limited to small, decades-old observational cohorts with variable blinding.

Single source

Most human and telomerase research comes from a single Russian research group.

Sources note that much of the published research (including the mortality datasets and telomerase findings) originates from Khavinson's St. Petersburg group over roughly four decades, and independent replication of the human clinical findings has been limited or absent. One source noted 266-patient mortality data came from 'one Russian lab.'

Contested

Replication of the telomerase/telomere effect is partial and its human relevance is unconfirmed.

The 2003 telomerase finding was reportedly replicated in vitro in 2025 (Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios, Epithalon: Research Evidence & Safety Profile | PeptideInsight, Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.), but other sources caution the telomerase reactivation has not been independently replicated in Western labs 'at the same magnitude' (Epitalon: 2026 Dosing & Telomere Evidence Review), that epigenetic binding-affinity data has not been broadly replicated (Epitalon: 2026 Dosing & Telomere Evidence Review), and that telomere effects are not confirmed in human clinical settings (Epithalon and Telomere Research: What Science Knows So Far - Peptides FYI).

Contested

Reported dosing varies enormously across sources, from sub-milligram to 10 mg daily.

Dosing recommendations range widely: 0.5-1.0 mg daily (Epitalon Peptide: Mechanism, Dosing & Safety | pin.board), 5 mg or 10 mg daily (Epithalon: The Telomere Peptide From Russia | PepAtlas), 5-10 mg daily (Epithalon Dosing, Need to Know Information, Safety,… | Peptide Initiative), and 10 mg IM daily in Russian/Ukrainian clinical protocols (Epithalon Monograph Final.pages). Course length (10-20 days), frequency (1-3x/year), and route also vary, and one review explicitly flags optimal dosing regimens as a knowledge gap.

Contested

Sources disagree on epithalon's plasma half-life and mechanism specifics.

Most sources report a plasma half-life of about 30 minutes with degradation within minutes (Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios, Epitalon: 2026 Dosing & Telomere Evidence Review, Epithalon: The Telomere Peptide From Russia | PepAtlas, How Long Epithalon Stays in System — Half-Life and), while one source estimates 2-4 hours (Epithalon Dosing, Need to Know Information, Safety,… | Peptide Initiative). There is also a species discrepancy on melatonin: epithalon reportedly failed to stimulate melatonin in rats but increased it in primates (Epithalamin/Epithalon).

Limited evidence

Much of the underlying literature is old, in Russian, and preclinical/mechanistic.

Roughly half of the ~110 published articles are in Russian (Epithalamin/Epithalon); a large share of substantive evidence is in vitro or animal (telomerase, lifespan, tumor, oocyte, gene-expression studies), and reviews note preclinical promise but a lack of clinical trials and systematic validation.

What you may have heard

The claims that make Epithalon famous — switching on telomerase, extending lifespan, and lowering mortality — are not backed by strong human evidence.

The only human study rated in the strongest evidence category looks narrowly at leukocyte circadian-gene expression and urinary melatonin markers (published in a Russian gerontology journal). It does not establish the peptide's marquee anti-aging claims. Telomerase activation and telomere lengthening come from cell-culture experiments (the 2003 Khavinson work and a 2025 replication in cell lines); lifespan extension comes from flies, mice, and rats; and the reduced-mortality figures come from small, unreplicated Russian cohorts, often combined with another peptide, thymalin. A lone strong observational study on circadian genes does not make the whole body of evidence robust.

Other

The 2025 finding that epithalon extends telomeres in telomerase-positive cancer cell lines is presented neutrally and no…

Overview reports epithalon extended telomeres in cancer lines (via ALT per Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.). Telomere elongation in malignant cells is a direct pro-survival/pro-proliferation signal, yet the safety section frames the oncology issue only as a 'theoretical' telomerase concern and reassures with animal tumor-reduction data. The in vitro cancer-cell telomere extension is a concrete, source-backed red flag the safety section omits.

What you may have heard

The claim that this peptide extends telomeres through a recombination-based mechanism in cancer cells rests on a single in vitro study.

One cell-line study, 'Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity', reports that in normal epithelial and fibroblast cells epitalon extended telomeres in a dose-dependent way through hTERT and telomerase upregulation, while in the breast cancer lines tested (21NT, BT474) telomere extension instead occurred through Alternative Lengthening of Telomeres (ALT) activation, with only minor ALT activity in normal cells. This normal-versus-cancer split in mechanism comes from that single study, and no independent replication is available to confirm the cell-type-specific switch.

What you may have heard

Histone binding energies of -56.49 and -64.51 kcal/mol are implausibly large for docking/binding scores.

Typical peptide/small-molecule docking or binding free energies fall roughly in the -5 to -20 kcal/mol range; values near -60 kcal/mol suggest a different computational method (e.g., MM/GBSA interaction energy) or a units/reporting error. Presenting these as binding energies without qualification may misrepresent the in silico result.

What you may have heard

'Functional effects last weeks to months' and 'nighttime melatonin persists for several days after a single dose' overst…

With a ~30 min plasma half-life, claims of effects lasting weeks-to-months (attributed claim 43) rest on in vitro hTERT mRNA timing and anecdotal melatonin persistence, not human PK/PD data. This disconnect is then used to justify pulsed dosing. The certainty of durable multi-week effects exceeds what the cited (largely tier-3/anecdotal) sources support.

What you may have heard

Antioxidant potency '~1000-fold more potent than epithalamin' and 'comparable to melatonin' is a questionable, strong co…

Epithalamin is a crude polypeptide extract, so a molar/concentration potency comparison against a pure tetrapeptide is not directly meaningful (1000-fold 'lower concentration' vs an undefined mixture). The 'comparable to melatonin' antioxidant claim is presented with more certainty than two sources (one tier 2, one tier 3) warrant.

Inconsistency

'Effective clearance within 24-48 hours' sits awkwardly with a 30-min half-life and 87.5% degradation in 90 minutes.

If ~87.5% is degraded within 90 minutes (≈3 half-lives), the compound is essentially gone within a few hours, not 24-48 hours. The two figures describe very different clearance timescales and should be reconciled or clarified (parent peptide vs fragments).

Inconsistency

Peptide described both as synthetic (developed in 1980s from epithalamin) and 'naturally occurring / first detected in t…

These framings coexist without reconciliation; the '2017 natural detection' claim leans on Epithalon: Research Evidence & Safety Profile | PeptideInsight/Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. and should be checked, since it materially affects whether epithalon is characterized as endogenous or a wholly synthetic construct.

What you may have heard

266-patient mortality data (1.6-4.1x fewer deaths) presented from a single tier-3 marketing source with a future-dated t…

Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios's title references an 'FDA PCAC Review Jul 2026' (a future date) and is a tier-3 commercial source; the striking mortality reduction figure is single-sourced and often confounded by co-administered thymalin. The caveat notes single-group origin but the specific magnitude deserves reviewer scrutiny for provenance.

Contested

The melatonin surge and the restored day-night rhythm are reported in two separate review articles about the same pineal tetrapeptide, not shown together in one documented study.

Both effects are described for the tetrapeptide Ala-Glu-Asp-Gly in old rhesus monkeys, but they come from different review-level sources and under slightly different names. '[Aging of the pineal gland]' reports that this peptide (there written Epithalon) produced a threefold increase in nocturnal melatonin peaks in old rhesus monkeys. 'Peptides and Ageing' reports that the same tetrapeptide (there written Epitalon) restored the circadian rhythms of melatonin and cortisol production in old rhesus monkeys. Both are summary reviews; neither source, as presented, details the underlying primary experiments or establishes that the two effects were observed in the same animals.

What you may have heard

The only top-tier human study of epithalon is a single small trial on circadian-gene activity; its headline telomerase and lifespan claims rest on lab-dish and animal experiments.

Epithalon is often presented as strongly evidenced, but the single strongest human study is a small observational trial showing it raised a melatonin breakdown product (6-sulfatoxymelatonin) about 1.7-fold and normalized circadian clock-gene expression (Clock, Csnk1e, Cry2) in people with reduced pineal function. The reasons most people are interested in epithalon — that it switches on telomerase, lengthens telomeres, extends lifespan, and lowers mortality — come from cell-culture experiments and rodent studies, largely from a single Russian research group, plus small unreplicated human cohorts. No human trial has confirmed the telomere or longevity claims.

Using it with other compounds

Check a stack
  • MOTS-cComplementary

    No documented conflict

    Both are longevity-oriented peptides converging on antioxidant defense and metabolic/mitochondrial health via distinct mechanisms — MOTS-c drives AMPK/PGC-1α mitochondrial biogenesis and NRF2 antioxidant response, while Epithalon works through telomerase, senescence-pathway, and circadian/antioxidant modulation. Complementary geroprotective strategies.

    Tier 4Theoretical — not established
  • SemaxComplementary

    No documented conflict

    Semax drives BDNF/NGF neurotrophin signaling for cognitive and neuroprotective effects, a mechanism distinct from Epithalon's antioxidant/senescence and circadian actions. The two hit neurogenesis and brain protection through separate pathways and may be complementary.

    Tier 4Theoretical — not established

    Shares neurogenesis

  • GHK-CuSame downstream effect

    No documented conflict

    Both peptides reduce oxidative stress by distinct routes. Epithalon shows antioxidant activity with mitochondrial ROS modulation and acts on telomerase and the p16/p21 senescence pathway. GHK-Cu activates antioxidant defenses (SOD/SOD2, reduced ROS) via SIRT1 and copper delivery to cuproenzymes including superoxide dismutase. They converge on antioxidant/mitochondrial function through different mechanisms. Nothing in their described biology suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares mitochondrial function

  • PinealonSame mechanism

    Worth caution

    Both are short Khavinson-school 'peptide bioregulators' proposed to act by binding DNA/histones and switching gene expression rather than a membrane receptor, and both are pitched as neuroprotective/neurogenic with effects on circadian and melatonin biology. Because they share the same class and proposed mechanism, running them together is largely redundant rather than additive — pick one for your goal rather than stacking two overlapping bioregulators.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although both are short peptides proposed to bind DNA or histones, that shared hypothesis does not establish they act through the same downstream pathways. Epithalon's documented mechanism centers on telomerase/hTERT and senescence markers (p16/p21), whereas Pinealon acts via MAPK/ERK, caspase-3/p53 apoptotic signaling, and antioxidant enzymes; their circadian, melatonin, and neurogenic effects are not shown to converge.

    Shares neurogenesis

  • HumaninComplementary

    No documented conflict

    Both are studied as geroprotective peptides that reduce oxidative stress and are reported to extend healthspan in animal models, but epithalon acts on telomerase/hTERT and circadian-melatonin gene regulation while humanin works through mitochondrial cytoprotection. Distinct anti-aging mechanisms with a shared longevity goal.

    Tier 4Theoretical — not established

    Shares mitochondrial function

  • FOXO4-DRIComplementary

    No documented conflict

    Both are anti-aging tools working from opposite ends of cellular senescence: FOXO4-DRI clears already-senescent p16/p21-positive cells (senolytic), whereas epithalon is reported to activate telomerase and delay cells from becoming senescent in the first place. Clearing existing senescent cells plus slowing new senescence is a mechanistically complementary pairing.

    Tier 4Theoretical — not established
  • SS-31Complementary

    No documented conflict

    SS-31 stabilizes cardiolipin and cuts mitochondrial ROS at the source, whereas Epithalon's reported benefits run through telomerase and general antioxidant/senescence pathways. Both reduce oxidative/mitochondrial aging burden via unrelated mechanisms, making them plausibly complementary.

    Tier 4Theoretical — not established

    Shares mitochondrial function

  • DSIPSame downstream effect

    May be complementary

    Both peptides converge on restoring normal melatonin secretion and circadian rhythm, but by different upstream mechanisms: DSIP influences pineal melatonin synthesis and delta sleep, while Epithalon reportedly upregulates the pineal melatonin (AANAT) axis and circadian clock genes. Used together they could reinforce circadian normalization and sleep timing.

    Tier 4Theoretical — not established

    Timing Take in the evening to reinforce the natural nighttime melatonin rise and consolidate circadian effects.

    Shares melatonin pathway

  • CerebrolysinComplementary

    No documented conflict

    Epithalon contributes antioxidant, geroprotective and neurogenic effects with mitochondrial ROS modulation, complementing Cerebrolysin's neurotrophic and energy-metabolism support. Different mechanisms converging on neuronal health; combination evidence is anecdotal.

    Tier 4Theoretical — not established

    Shares mitochondrial function · neurogenesis

Safety and side effects

Safety and Tolerability

Epithalon and its parent extract epithalamin are generally described as well tolerated with a favorable safety profile, with no consistent pattern of serious toxicity at the doses studied. Two 3-year epithalamin treatment trials (one with 12-year follow-up) reported no severe adverse events in older adults, and limited evidence suggests epithalamin is likely safe for long-term use.

Reported Adverse Effects

Reported adverse effects and user experiences are typically mild and self-limiting, and are consistent with pineal/circadian axis activation:

  • Vivid dreams (reported almost universally)
  • Deep sleep during the first few nights
  • Mild next-day drowsiness at higher doses
  • Minor, brief injection-site tenderness

Theoretical and Unresolved Concerns

  • Telomerase and oncology: There is a theoretical oncological concern about inducing telomerase activity in adult somatic cells — a phenomenon rare outside stem-cell and germline contexts. This concern has not been adequately addressed. Notably, animal data point in the opposite direction (reduced spontaneous and induced tumor incidence), but the theoretical risk in humans remains unresolved.
  • Lack of long-term human safety data: As a non-approved peptide, epithalon lacks long-term safety data and systematic validation.
  • Limited, single-group human data: Human safety observations come largely from small cohorts, many from a single Russian research group, without independent confirmation.

Regulatory Note

Epithalon is unscheduled and not approved for any indication in the US, has had no FDA or EMA review, carries an FDA Category 2 designation (Oct 2023), and is banned from compounding. It should be regarded as a research compound.

  • Telomere extension observed in cancer cells: Beyond the general theoretical concern, a 2025 in vitro study (Siddiqui/Al-Dulaimi et al., PMID 40908429) reported that epithalon extended telomeres in telomerase-positive breast cancer cell lines, primarily via the Alternative Lengthening of Telomeres (ALT) pathway. Telomere elongation in malignant cells is a pro-survival/pro-proliferation signal, so this is a concrete laboratory observation rather than a purely hypothetical risk. Its clinical significance in humans is unknown and has not been studied, but anyone with a personal or strong family history of cancer should weigh it and consult a clinician before use.

Reconstitution and handling

Reconstitution

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

Epithalon is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before use. A commonly described preparation:

  • A 10 mg vial reconstituted with 2 mL bacteriostatic water yields a concentration of 5 mg/mL.
  • At that concentration, a 5 mg dose corresponds to 100 units (1.0 mL) on a U-100 insulin syringe.

Bacteriostatic water is directed slowly against the vial wall; the powder is allowed to dissolve without vigorous shaking. Reconstituted solution is typically refrigerated.

Route of Administration

Epithalon is orally inactive. The standard research route is subcutaneous injection. Some studies of the parent pineal preparation used intramuscular or intranasal routes.

Reported Dosing Protocols (research/community)

Reported dosing varies enormously across low-tier secondary and community sources — from sub-milligram to 10 mg daily — and optimal regimens are explicitly flagged as a knowledge gap. Reported ranges include:

  • Common community/protocol dosing: 10-20 day courses repeated 1-2 (or 1-3) times per year. A protocol frequently cited in tier-3 community sources (e.g., PepAtlas) is 5 mg SC daily for 20 consecutive days, or 10 mg daily for 10 days, with 4-6 month off periods.
  • Lower-dose reports (tier-3 community sources such as pin.board): 0.5-1.0 mg daily SC for 10-20 days, twice per year; or 5-10 mg daily for 10-20 day courses, with courses repeated monthly or quarterly.
  • Russian/Ukrainian intramuscular protocols (reported in tier-3 community sources): 100 mg total (10 mg IM daily for 10 days, twice a year), or 50 mg total (10 mg every third day over 2 weeks, twice a year).

Pharmacokinetic Context

Despite a short plasma half-life (~30 minutes per most sources; up to 2-4 hours per one source), reported functional effects persist much longer — telomerase (hTERT mRNA) activation peaks 24-36 hours post-injection in vitro, and elevated nighttime melatonin reportedly persists for several days after a single dose. This apparent disconnect between rapid clearance and prolonged downstream effects is often cited as a rationale for intermittent, pulsed course-based dosing rather than continuous administration.

Important Note

These figures are reported research and community protocols, not medical guidance. Epithalon is a non-approved research compound with no established human dosing standard, and reported protocols conflict widely.

Sources

Ordered by evidence quality — the strongest first.

  1. [AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  2. Epithalon Peptide Induces Telomerase Activity and ...(opens in a new tab)
    Tier 2Web · researchgate.net
  3. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  4. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide ...(opens in a new tab)
    Tier 2Web · pubmed.ncbi.nlm.nih.gov · 2025
  5. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  6. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  7. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  8. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  9. Short Peptides Protect Oral Stem Cells from Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  10. [Aging of the pineal gland].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  11. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  12. Peptides and Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  13. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  14. Epitalon Peptide: Mechanism, Dosing & Safety | pin.board(opens in a new tab)
    Tier 3Web · blog.pinned.life
  15. Epithalamin/Epithalon(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  16. Epithalon: The Telomere Peptide From Russia | PepAtlas(opens in a new tab)
    Tier 3Web · pepatlas.com · 2026
  17. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  18. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  19. Peptide Regulation of Cell Differentiation.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  20. An Efficient Data-Gathering Routing Protocol for Underwater Wireless Sensor Networks.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2015

See something wrong or out of date on this page? Report it.